There is no safe level of drinking alcohol, concludes a new study. The study, published today in the international medical journal The Lancet, shows that in Globally, more than 2 billion people were current drinkers in ; 63% were male. We need to act urgently to prevent these millions of deaths. Nearly six million Americans have bipolar disorder, and most have probably After searching 12 years for bipolar disorder's cause, research team concludes it has many Date: December 15, ; Source: Michigan Medicine - University of In fact, they say, no one genetic change, or chemical imbalance, or life event. Rigorous exercise does not halt dementia decline, study concludes and some small studies have been done in dementia patients with positive results. Sarah Lamb, lead author of a paper in the British Medical Journal. “I “We don't want to alarm members of the public with dementia and their families.
More Research We Need Medical That… Research Concludes The
The new research is important because it reminds us that — given the damage done by alcohol misuse — strong public-health initiatives are necessary. Taxation, minimum pricing, restrictions on advertising, labelling and public education and guidelines are all important measures to reduce the potential harms caused by alcohol. Cheap, readily available alcohol and buck-a-beer policies are bad for public health.
But so, too, is a prohibitionist mindset. Where the authors of the new research went astray was with the suggestion that public-health officials should promote abstinence. There is no justification for that recommendation in the data. It is gratuitous moralism. When it interferes with daily living, it stops being fun and starts being a health risk.
This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.
If you would like to write a letter to the editor, please forward it to letters globeandmail. Readers can also interact with The Globe on Facebook and Twitter. Comments that violate our community guidelines will be removed.
Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments. Read our community guidelines here. Site navigation Your reading history.
Article text size A. To view your reading history, you must be logged in. Published August 27, Updated August 27, Story continues below advertisement. Report an error Editorial code of conduct. Log in Subscribe to comment Why do I need to subscribe? I'm a print subscriber, link to my account Subscribe to comment Why do I need to subscribe?
We aim to create a safe and valuable space for discussion and debate. All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments. Treat others as you wish to be treated Criticize ideas, not people Stay on topic Avoid the use of toxic and offensive language Flag bad behaviour Comments that violate our community guidelines will be removed.
Read most recent letters to the editor. Due to technical reasons, we have temporarily removed commenting from our articles. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies. To find relevant articles please visit here to pick a cluster. Emma Wilkinson is a freelance journalist specialising in biosciences, medicine and health policy.
She started out at The Lancet, before moving to Pulse to work as a clinical reporter where she won several awards. Other staff positions include four years as a health reporter at BBC News online. Emma now splits her time between writing, editing and teaching at both Sheffield Hallam University and the University of Sheffield where she helped develop the MSc in Science Communication. Methylphenidate should be the first-line option to treat children with attention deficit hyperactivity disorder, according to a review of the safety and efficacy of seven drugs.
The research, which looked at evidence on the safety and efficacy of seven drugs used to treat the condition, also recommended that amphetamines should be the first choice in adults who have ADHD. However, more evidence is needed on long-term effects of the drugs, and environmental modifications and other non-pharmacological treatments should be tried first, the researchers concluded in The Lancet Psychiatry on 7 August In a large meta-analysis and systematic review, researchers looked at evidence from double-blind randomised controlled trials — including 81 trials in children — for lisdexamfetamine, atomoxetine, bupropion, clonidine, guanfacine, methylphenidate and modafinil, compared with placebo over 12 weeks of treatment.
For the short-term treatment of ADHD, all of the drugs, except modafinil in adults, were more effective than placebo but were less effective and less tolerable in adults than children and adolescents, although it was unclear why. The National Institute for Health and Care Excellence NICE already recommends methylphenidate as first-line drug treatment for children aged five years and over and young people with ADHD, with lisdexamfetamine and atomoxetine or guanfacine recommended as second and third options.
In adults, NICE recommends methylphenidate and lisdexamfetamine as first-line treatments, but other European guidelines recommend psychostimulants as first-line options with no distinctions. Andrea Cipriani, study lead and associate lecturer in the department of psychiatry at the University of Oxford, UK, said medication could be an important tool for ADHD and the evidence showed these were safe and effective treatments in the short term.
New research should be funded urgently to assess the long-term effects of these drugs, the researchers concluded. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: For commenting, please login or register as a user and agree to our Community Guidelines.
You will be re-directed back to this page where you will have the ability to comment. A one-stop source for the proper conduct of clinical trials. Essential information on clinical trial design and pharmacovigilance. Over 90 case studies based on real life patient-care scenarios. Each case includes learning outcomes and references.
New research concludes there is no safe level of alcohol. But look beyond the alarmist headlines
The new research provides evidence that moderate drinking poses little serious health risk. of a massive new study published in the medical journal The Lancet. for your heart, the benefit is more than offset by an increased risk of cancer. What we need to do is balance the risks of activities against the. Perhaps the most familiar form of health research is the clinical trial, in which patients Many other examples of findings from medical records research have . More than two-thirds of respondents said they would be willing to participate in a .. health research concluded that public involvement in research is necessary for. But new research published in the Medical Journal of Australia has found that British secret agent James Bond has a serious drinking problem. More Information Tackling the haters: Why we could have a female Bond.